Detalhe da pesquisa
1.
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.
BMC Cancer
; 23(1): 136, 2023 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36765293
2.
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer.
Future Oncol
; 19(10): 727-736, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37133230
3.
Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.
BMC Cancer
; 23(1): 192, 2023 Feb 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36849943
4.
Pretreatment PLR Is Preferable to NLR and LMR as a Predictor in Locally Advanced and Metastatic Bladder Cancer.
Cancer Diagn Progn
; 3(6): 706-715, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37927800
5.
The Effect of Continuing Chemotherapy after Chemoradiotherapy during the Time to Surgery on Tumor Response and Survival for Local Advanced Rectal Cancer.
J Oncol
; 2022: 4108677, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36157223